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Background: Colorectal cancer is among the leading causes of cancer and cancer-related mortality in the United
States. The incidence and mortality associated with CRC can be reduced with preventive screening. Inadequate
bowel preparation has been associated with missed adenomas and the need for repeat colonoscopies.
Methods: Separate claims source databases were analyzed to determine the costs associated with colonoscopy in
the commercial and Medicare populations. Observed repeat rates for colonoscopy within 4 years of initial screening
were also examined.
Results: Among the 6 most commonly used billing codes, the average allowed cost for an episode of colonoscopy
in 2010 was $2,146 in the commercial population and $1,071 in the Medicare population, with average cost sharing
of $334 and $275, respectively. The portion of colonoscopies associated with a biopsy or polyp removal exceeded
50% in the commercial and Medicare populations. Approximately 57% of colonoscopies in the commercial
population were associated with claims for a prescription bowel preparation product within 30 days prior to the
procedure. Three branded and three generic bowel cleansing products accounted for approximately 75% of the
total number of prescription claims for colonoscopy. Given literature reports that up to 25% of patients receive
inadequate bowel preparation, the rate of repeat colonoscopy within 4 years of initial screening was lower than
expected among patients who were not coded with common clinical reasons for early repeat: benign neoplasm,
lesion, or polyp removed at initial screening colonoscopy.
Conclusions: The reported rates of inadequate bowel preparation are 15% to 25%, but the rates of repeat
colonoscopy found in our analysis are much lower; this is a risk concern considering the reported, significant miss
rate of adenomas secondary to inadequate bowel preparation.
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Colorectal cancer (CRC) is the fourth leading cause of
cancer and the second leading cause of cancer deaths
after lung cancer in the United States [1]. The lifetime
risk of developing CRC is approximately 1 in 20 for both
males and females [1]. CRC develops slowly over a
period of several years [2], allowing an opportunity for
screening and prevention.
CRC is one of the most preventable cancers, which
helps explain why CRC screening has become a public
health priority in recent years. Several groups, including* Correspondence: bruce.pyenson@milliman.com
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reproduction in any medium, provided the orthe US Multi-Society Task Force on CRC, American College
of Gastroenterology, US Preventive Services Task Force,
and National Comprehensive Cancer Network, have
published recommendations for CRC screening [3-6]. A
patient’s screening strategy will depend on the individ-
ual’s risk, age, family history of CRC, and incidence of
other serious gastrointestinal conditions. However,
starting at 50 years of age, an individual of average risk
for CRC should begin regular screening for CRC.
Screening may include annual fecal occult blood tests
or fecal immunochemical tests (with colonoscopy re-
served for patients testing positive for CRC) or endo-
scopic procedures performed every 5 years for flexiblel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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some patients, more frequent screening or the use of a
stool DNA test or computed tomography colonoscopy
may be appropriate.
Screening of any type considerably reduces the mortality
associated with the disease [7]. In average-risk patients,
screening with colonoscopy has been demonstrated to de-
crease the incidence of CRC by 67% and CRC deaths by
65% [8]. Furthermore, colonoscopic screening and re-
moval of adenomatous polyps reduced the mortality from
CRC by 53% relative to the incidence-based mortality
from CRC in the general population [9].
Screening for CRC remains underused compared with
breast and cervical cancer screening. Data from the 2010
National Health Interview survey indicated that compli-
ance with recommended screening for breast and cervical
cancer exceeded 72% [10]. However, among adults 50 years
and older 58.6% are current with recommended CRC
screening according to data from the recent National
Health Interview or 65.4% according to the telephonic
Behavioral Risk Factor Surveillance surveys [10]. These es-
timates are below the 75% goal set by the American Can-
cer Society and the 70.5% goal set by the Department of
Health and Human Services for adults ≥ 50 years [11,12].
Colonoscopy provides a visual diagnosis of inflamed tis-
sues, abnormal growths, ulcers, and bleeding from the
rectum and colon to the small intestine. It allows for both
diagnostic assessment of the colon and certain therapeutic
interventions (removal of polyps) during the same proced-
ure. Poor bowel preparation deters procedural success
and may lead to missed polyps and cancer [13], prolonged
procedural time to clean the colon, and cancelled proce-
dures [14]. Rates of poor preparation are commonly re-
ported between about 15% and 25% [15-17], and can lead
to a recommendation for repeat colonoscopy.
The objectives of this manuscript are to 1) analyze the
average cost and cost sharing associated with screening
colonoscopy, including the cost of products for bowel
preparation, among the most commonly reported pro-
cedure codes in the commercial and Medicare popula-
tions, and 2) determine the repeat rate of colonoscopy in
patients without evidence of high risk for CRC in the
commercial and Medicare populations. We report the
repeat rate separately for patients depending on whether
the initial colonoscopy procedure included a biopsy or
removal of polyp. We refer to the repeat rate for patients
with an initial colonoscopy procedure not including a bi-
opsy or removal of polyp as the “more restrictive” repeat
rate. The repeat rate for all selected patients is referred
to as the “less restrictive” repeat rate.
Methods
Two claims source databases were used in this analysis;
the commercial population data was derived fromTruven MarketScan® and the Medicare population data
was gathered from the Medicare 5% beneficiary sample.
MarketScan includes inpatient, outpatient, and drug
claims for individuals covered by benefit plans of large
employers, health insurers, and government employers.
Insured groups with high deductible health plans or
capitation, and individuals >65 years or not associated
with an active employee were excluded from the com-
mercial population analysis. The Medicare 5% benefi-
ciary sample is a limited data set that contains all
Medicare Part A and Part B paid claims generated by a
sample of Medicare beneficiaries. Exclusions in the
Medicare population analysis included beneficiaries who
were disabled, institutionalized, eligible for Medicaid, or
enrolled in a health maintenance organization.
Screening colonoscopy
To determine the cost of screening colonoscopy in the
commercial and Medicare populations, colonoscopies per-
formed in 2010 with a selected Healthcare Common Pro-
cedure Coding System (HCPCS) code were selected after
exclusions for patients identified as having pre-exisitng
high risk conditions based on International Classification
of Disease (ICD-9) diagnosis codes. International Classifi-
cation of Disease (ICD-9) diagnosis codes were analyzed
(Table 1). All costs on the day of colonoscopy for outpa-
tients were included. All facility costs for inpatients were
excluded.
The average allowed and paid costs and patient cost
sharing were analyzed in both populations. Claims for
bowel preparation prescriptions, percentage of colonos-
copies with prescriptions filled within 30 days prior to
the date of screening colonoscopy, and the average cost
of bowel preparation were evaluated in the commercial
population.
The allowed amount for a service is a dollar amount
typically considered payment-in-full for a member insured
by an insurance company and its associated network of
healthcare providers. The allowed amount is typically a
discounted rate rather than the provider’s actual charge.
The insurer directly pays the healthcare provider the paid
amount. The patient bears responsibility for cost sharing,
which may include copays, coinsurances, and deductibles.
Repeat screening colonoscopy
To examine the repeat rate of screening colonoscopy in
the commercial and Medicare populations, colonos-
copies performed in 2005 with a repeat colonoscopy
within 4 years (48 months in commercial population; 16
quarters in Medicare population) with an eligible
HCPCS code and an eligible ICD-9 diagnosis code
(Table 1) were analyzed. Colonoscopies beyond the first
repeat screening were ignored. Patients without continu-
ous enrollment throughout the study period were
Table 1 Eligible codes to identify screening colonoscopies of interest
Code Definition
Healthcare Common Practice Coding System (HCPCS)
45378 Diagnostic/screening colonoscopy for non-Medicare patients
45380 Colonoscopy with biopsy single/multiple
45383 Colonoscopy with ablation of tumors, polyps, or other lesions not
amenable to removal by hot biopsy forceps
45384 Removal of polyps or other lesions by hot biopsy
45385 Removal of polyps or other lesions by snare technique
G0121 Screening colonoscopy for other Medicare patients
International Classification of Disease (ICD-9) Diagnosis for excluding patients with pre-existing high-risk conditions
V76.51 Special screening for malignant neoplasm, colon
211.3 Benign neoplasm of other parts of digestive system, colon
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condition that would justify a follow-up before the usual
10 year period; these were colonoscopies whose code in-
dicated a biopsy or removal of a benign neoplasm, le-
sion, or polyp occurred during the initial screening
colonoscopy (HCPCS codes: 45378 and G0121; ICD-9
code: V76.51). The repeat rate for colonoscopy patients
whose initial colonoscopy did not include one of these
biopsy or polyp removal procedures was tabulated sepa-
rately, which is characterized as the more restrictive re-
peat rate. The less restrictive repeat rate calculation
includes all patients with an initial colonoscopy (HCPCS
codes: 45378, 45380, 45383, 45384, 45385, or G0121;
and ICD-9 codes: V76.51 or 211.3). The sample sizes for
the less restrictive cohorts were 22,044 and 24,720 for
commercial and Medicare, respectively. The sample sizes




% N = 489,575
All screening colonoscopies 100







Colonoscopies with modifiers* 22, 52, 53, 73, and 74 0.4
Colonoscopies with other modifiers 11.2
* 22 = Service provided is greater than that usually required for the listed procedure
52 = A service or procedure is partially reduced at the physician’s discretion.
53 = Termination of a surgical or diagnostic procedure due to extenuating circumst
73 = Discontinued outpatient hospital/ambulatory surgery center procedure prior to
74 = Discontinued outpatient hospital/ambulatory surgery center procedure after adfor commercial and Medicare, respectively. Comparisons
within the commercial and within the Medicare populations
examined the percent of repeat screening colonoscopies




In the databases used, the total number of eligible
screening colonoscopies performed in 2010 was 489,575
in the commercial population and 56,496 in the Medi-
care population. Data regarding costs associated with
screening colonoscopy claims are summarized in Table 2
for the commercial population and Table 3 for the Medi-
care population. Among the procedure codes used for
screening colonoscopies, the average allowed amount for
commercial claims was about twice the amount allowedulation
Average per colonoscopy
Allowed Paid Cost share Coinsurance
%$ $ $
2,146 1,812 334 15.6
2,096 1,780 316 15.1
1,769 1,546 222 12.6
2,309 1,935 374 16.2
2,568 2,127 440 17.2
2,419 2,018 400 16.6
2,332 1,945 386 16.6
1,664 1,454 210 12.6
1,911 1,650 260 13.6
2,548 2,071 477 18.7
.
ances or those that threaten the well-being of the patient.
the administration of anesthesia.
ministration of anesthesia.




% N = 56,496
Average per colonoscopy
Allowed Paid Cost share Coinsurance
%$ $ $
All screening colonoscopies 100 1,071 795 275 25.7
Colonoscopies with no modifiers 86.3 1,073 795 278 25.9
45378 4.8 836 606 229 27.5
45380 22.5 1,057 784 272 25.8
45383 2.6 1,240 917 323 26.1
45384 8.2 1,139 834 305 26.8
45385 35.7 1,196 889 307 25.7
G0121 12.4 762 564 198 26.0
Colonoscopies with modifiers
0.8 849 623 225 26.6
22, 52, 53, 73, and 74 *
Colonoscopies with other modifiers 13.0 1,067 808 258 24.2
* 22 = Service provided is greater than that usually required for the listed procedure.
52 = A service or procedure is partially reduced at the physician’s discretion.
53 = Termination of a surgical or diagnostic procedure due to extenuating circumstances or those that threaten the well-being of the patient.
73 = Discontinued outpatient hospital/ambulatory surgery center procedure prior to the administration of anesthesia.
74 = Discontinued outpatient hospital/ambulatory surgery center procedure after administration of anesthesia.
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ciary cost sharing for screening colonoscopy was 15.6%
in the commercial population and 25.7% in the Medicare
population. Compared with the commercial population,
the portion of claims in the Medicare population with a
colonoscopy that included a code for biopsy or polyp
removal was about 25% higher (51.6% vs 69.0%). The
majority of claims (>85%) in the commercial and Medi-
care populations had no modifier codes and less than 1%
of claims were associated with codes for discontinuation
(53, 73, and 74) or the need to spend additional time
cleaning the colon (22 and 52).
Over half of the people obtaining colonoscopies in the
commercial analysis (56.6%) had a claim for a prescription
bowel preparation within 30 days prior to the procedure.
Approximately 100 different National Drug Codes wereTable 4 Common bowel preparation prescriptions filled withi
population
National











68220013104 Trilyteidentified for products that could be for bowel preparation
and nearly 60% of all bowel preparation claims were for
a branded product. Six bowel preparation products
accounted for approximately 75% of the total number
of prescriptions; this included 3 branded and 3 generic
products (Table 4). The average cost sharing for
branded products was $29.62 and that of generic prod-
ucts was $8.31. The allowed or paid cost associated
with bowel preparation products was under 1% of the
average allowed or paid cost, respectively, of the colon-
oscopy in the commercial population.
Approximately 43% of screening colonoscopies in the
commercial population did not have a claim for a pre-
scription bowel preparation within 30 days prior to the
procedure. Although patients may have filled the pre-





Allowed Paid Cost share
$ $ $
42.1 16.83 8.52 8.31
27.9 48.89 17.38 31.52
14.2 53.72 26.53 27.19
6.0 66.40 31.65 34.76
57.7 50.50 20.88 29.62
15.0 18.32 9.69 8.63
6.1 10.43 3.00 7.43
6.0 20.01 10.81 9.20
Figure 1 Cumulative colonoscopies repeated within 48 months following initial screening colonoscopy in the commercial population.
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counter bowel cleansing products that are paid by the
patient. Popular over-the-counter products general cost
less than $25.Repeat screening colonoscopy
Using the less restrictive repeat rate criteria, the por-
tion of patients obtaining a repeat screening colonos-
copy within 4 years of the initial screening was 12.6%
and 19.8% for the commercial (n = 22,044) and Medicare
(n = 24,720) cohorts, respectively. Using the more restrict-
ive repeat rate criteria, the percentage of repeat screening
colonoscopies within 4 years of the initial screening
colonoscopy was 3.5% and 3.8% for the commercialFigure 2 Cumulative colonoscopies repeated within 16 quarters follo(n = 8,133) and Medicare (n = 5,858) cohorts, respect-
ively. See Figures 1 and 2.
Discussion
Treating CRC is expensive; based on Medicare data from
2008 and 2009 we found the average cost is estimated at
$43,000 within the first 12 months after diagnosis, not
including prescription drug expense. Analysis of the
MarketScan and Medicare 5% beneficiary sample claims
databases indicated that the average allowed cost in
2010 for screening colonoscopy was $2,146 for commer-
cial payers and $1,071 for Medicare patients. Colonos-
copy has been established as a cost-effective screening
technique because it reduces mortality at relatively low
incremental costs on a population basis [18].wing initial screening colonoscopy in the Medicare population.
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copies did not have a claim for a prescription bowel
preparation within 30 days prior to the procedure, sug-
gesting the use of over-the-counter products in many
patients.
Research indicates that approximately 1 in 4 to 1 in 6
patients are inadequately cleansed in preparation for col-
onoscopy [15-17]. Guidelines from the American Cancer
Society and US Multi-Society Task Force on Colorectal
Cancer recommend repeating the screening colonoscopy
before planning a long-term surveillance program if the
colon is not adequately prepared [19]. Given the high
percentage of patients with inadequate preparation, the
rate of repeat colonoscopy was anticipated to be higher
than what was found in the commercial and Medicare
populations. With suboptimal preparation, some clini-
cians may opt to recommend a shorter follow-up inter-
val rather than repeat the colonoscopy [20], although
our 4 year follow-up may include repeat colonoscopies
as well as some with a shorter follow-up interval. The
recent American College of Physician’s clinical guidance
on colorectal cancer screening notes concern with over-
use of colonoscopy as well as under-use, and the source
databases are expected to include both [21]. The low
rate of repeats found in our data is of concern as re-
search indicates miss rate of adenomas secondary to in-
adequate bowel preparation is significant. Lebwohl
reports 43% of adenomas were missed among asymp-
tomatic patients undergoing repeat colonoscopy [16];
Chokshi reports 34% missed adenomas among average
risk patients undergoing repeat colonoscopies, where
repeats in both studies were due to inadequate prepar-
ation [13].
A limitation of this analysis is that the data did not
capture the level of bowel preparation quality. In
addition, the analysis relies on claims coding to make in-
ferences, which can introduce biases such as caused by
miscoding or under-coding. Also, the data from the ana-
lysis is based on historical numbers, and may not be ap-
propriate for any one particular organization given the
variability in health care benefits. However, the use of
claims databases to identify individuals who have had
screening colonoscopy seems supported by a recent
comparison of medical records and claims [22].
Tabulating repeat rates only for lives having four years
of continuous enrollment allowed for complete follow-
up for all initial colonoscopies, but it could have intro-
duced biases. For the commercial population, breaks in
enrollment in the source database are typically due to
shifts in employment or changing coverage such as
obtaining Medicare coverage through aging or disability.
Such individuals would have been excluded, and such in-
dividuals could be less healthy than those with continu-
ous enrollment. For the Medicare population, breaks inenrollment are typically due to entry into Medicare Ad-
vantage or death. The impact of the continuous enroll-
ment criteria on the results is unclear.
Conclusions
The average allowed cost in 2010 for screening colonos-
copy was $2,146 for commercial payers and $1,071 for
Medicare patients. Given the reportedly high rates of pa-
tients with inadequate preparation for colonoscopy, the
rate of repeat colonoscopy was anticipated to be higher
than what was found in the commercial and Medicare
populations. This is of risk concern because of signifi-
cant miss rates of adenomas secondary to inadequate
bowel preparation.
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